证券代码：600594 证券简称：益佰制药 公告编号：2025-027 贵州益佰制药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 重要内容提示： 会议召开时间：2025 年 9 月 3 日 星期三 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动方式 投资者可于 2025 年 8 月 27 日（星期三）至 9 月 2 日（星期二）16:00 前 登录上证路演中心网站首页点击"预征集问答"栏目或通过贵州益佰制药股份有 限公司（以下简称"公司"）邮箱（600594@gz100.cn）进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 公 司 已 于 2025 年 8 月 21 日 在 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn/）披露了《贵州益佰制药股份有限公司 2025 年半年 度报告》及其摘要，为便于广大投资者更全面深入地了解公司 2025 年半年度财 务状况、经营成果，公司计划于 ...

Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing a significant surge in stock performance, driven by strong policy support and increasing market demand for TCM products [1][2]. Group 1: Market Performance - The TCM sector has shown rapid growth, with companies like Xintian Pharmaceutical leading the charge by hitting the daily limit on stock price increases, accompanied by a notable increase in trading volume [1]. - Other companies in the sector, such as Yibai Pharmaceutical, Zhendong Pharmaceutical, and others, are also witnessing substantial gains, indicating a broad-based rally within the TCM industry [1]. Group 2: Policy Support - The Chinese government is enhancing support for the TCM industry, as evidenced by the State Council's issuance of guidelines aimed at improving TCM quality and promoting high-quality development within the sector [1][2]. - The guidelines emphasize the protection and utilization of TCM resources, as well as optimizing the industrial structure and strengthening the TCM supply chain [1]. Group 3: Market Demand - There is a growing demand for TCM driven by increasing health awareness among the population and the aging demographic, which is expected to continue fueling the sector's growth [1][2]. - The expansion of the TCM market is anticipated to create new opportunities in related fields, such as TCM raw material cultivation, which will benefit farmers and agricultural service providers [1]. Group 4: Related Sectors - The TCM research and development sector is poised to benefit from government encouragement for innovation, leading to increased investment in new TCM drugs and classic formulations [2]. - The healthcare sector is closely linked to TCM, with the development of TCM products expected to drive innovation and upgrades in healthcare offerings, including TCM therapies and wellness services [2]. Group 5: Challenges and Future Potential - Despite the positive outlook, the TCM industry faces challenges such as the need for unified quality standards and sustainable resource utilization [2]. - However, the combination of policy support, growing market demand, and the industry's own development trends suggests that the TCM sector and its related fields have significant growth potential in the future [2].

据证券之星公开数据整理，近期益佰制药（600594）发布2025年中报。根据财报显示，益佰制药亏损收 窄。截至本报告期末，公司营业总收入9.93亿元，同比下降14.99%，归母净利润-1990.21万元，同比上 升81.31%。按单季度数据看，第二季度营业总收入4.92亿元，同比下降17.45%，第二季度归母净利 润-1051.63万元，同比上升72.35%。 本次财报公布的各项数据指标表现一般。其中，毛利率60.65%，同比减2.87%，净利率-2.25%，同比增 76.3%，销售费用、管理费用、财务费用总计5.63亿元，三费占营收比56.68%，同比减12.65%，每股净 资产3.12元，同比减9.39%，每股经营性现金流0.22元，同比减16.02%，每股收益-0.03元，同比增 81.34% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 11.68 Z | 22666 | -14.99% | | 归母浄利润（元） | -1.06亿 | -1990.21万 | 81.31% | | 扣非净利润(元) | ...

截至2025年8月21日15时，益佰制药股价报4.48元，较前一交易日下跌1.54%，成交额2.51亿元。 益佰制药主营业务涵盖医药工业和医疗服务板块，主要产品包括中药制剂、化学药及医疗服务等。公司 近期因产品停产及商业贿赂风波受到市场关注。 消息面上，益佰制药披露2025年半年报，上半年营收9.93亿元，同比下降14.99%，归母净利润亏损 1990.21万元，但较去年同期亏损幅度收窄。公司拟以8000万元收购控股子公司剩余股权，以整合资 产。此外，公司小儿止咳糖浆因生产缺陷被暂停销售，但该产品占营收比例较小，预计对业绩影响有 限。 资金流向方面，益佰制药8月21日主力资金净流出2371.04万元，近五日主力资金净流入4590.07万元。 风险提示：股市有风险，投资需谨慎。 来源：金融界 ...

Group 1 - Xiamen Tungsten's revenue for the first half of 2025 reached 19.178 billion yuan, an increase of 11.75% year-on-year [1] - Xiamen Tungsten's net profit attributable to shareholders decreased by 4.37% year-on-year to 972 million yuan [1] - Xiamen Tungsten plans to distribute a cash dividend of 1.84 yuan per 10 shares [1] Group 2 - Sinopec's revenue for the first half of 2025 was 1.41 trillion yuan, a decrease of 10.6% year-on-year [1][2] - Sinopec's net profit attributable to shareholders fell by 39.8% year-on-year to 21.483 billion yuan [1][2] - Sinopec's basic earnings per share were 0.177 yuan [1] Group 3 - Xinhua Department Store's revenue for the first half of 2025 was 3.254 billion yuan, a decrease of 0.99% year-on-year [3][4] - Xinhua Department Store's net profit attributable to shareholders decreased by 2.52% year-on-year to 86.08 million yuan [3][4] - Xinhua Department Store plans to distribute a cash dividend of 1 yuan per 10 shares [3] Group 4 - Huaqin Technology's revenue for the first half of 2025 reached 516 million yuan, an increase of 6.44% year-on-year [5][6] - Huaqin Technology's net profit attributable to shareholders decreased by 32.45% year-on-year to 146 million yuan [5][6] - Huaqin Technology plans to distribute a cash dividend of 1.3 yuan per 10 shares [5] Group 5 - Tianhao Energy's revenue for the first half of 2025 was 1.372 billion yuan, a decrease of 32.15% year-on-year [7] - Tianhao Energy's net profit attributable to shareholders decreased by 32.08% year-on-year to 69.01 million yuan [7] - Tianhao Energy's basic earnings per share were 0.0798 yuan [7] Group 6 - Wanliyang's revenue for the first half of 2025 reached 2.812 billion yuan, an increase of 2.69% year-on-year [8][9] - Wanliyang's net profit attributable to shareholders increased by 50.24% year-on-year to 277 million yuan [8][9] - Wanliyang's basic earnings per share were 0.21 yuan [8] Group 7 - Kede CNC's revenue for the first half of 2025 was 295 million yuan, an increase of 15.24% year-on-year [10] - Kede CNC's net profit attributable to shareholders increased by 1.27% year-on-year to 49.06 million yuan [10] - Kede CNC's basic earnings per share were 0.4582 yuan [10] Group 8 - Saifutian's revenue for the first half of 2025 reached 1.06 billion yuan, an increase of 62.41% year-on-year [11] - Saifutian achieved a net profit of 3.08 million yuan, recovering from a loss of 12.49 million yuan in the previous year [11] - Saifutian's basic earnings per share were 0.01 yuan [11] Group 9 - Funeng's revenue for the first half of 2025 was 6.369 billion yuan, a decrease of 4.44% year-on-year [13][14] - Funeng's net profit attributable to shareholders increased by 12.48% year-on-year to 1.337 billion yuan [13][14] - Funeng plans to distribute a cash dividend of 0.73 yuan per 10 shares [13] Group 10 - Ningbo Shipping reported a net loss of 39.23 million yuan for the first half of 2025 [15][16] - Ningbo Shipping's revenue for the first half of 2025 was 1.157 billion yuan, an increase of 11.33% year-on-year [15][16] - Ningbo Shipping's basic earnings per share were a loss of 0.0325 yuan [15] Group 11 - Samsung Medical's revenue for the first half of 2025 reached 7.972 billion yuan, an increase of 13.93% year-on-year [17][18] - Samsung Medical's net profit attributable to shareholders increased by 6.93% year-on-year to 1.23 billion yuan [17][18] - Samsung Medical plans to distribute a cash dividend of 4.85 yuan per 10 shares [17] Group 12 - Huiding Technology's revenue for the first half of 2025 was 2.251 billion yuan, a decrease of 0.20% year-on-year [20] - Huiding Technology's net profit attributable to shareholders increased by 35.74% year-on-year to 431 million yuan [20] - Huiding Technology plans to distribute a cash dividend of 0.15 yuan per share [20] Group 13 - Baihua Pharmaceutical's revenue for the first half of 2025 reached 202 million yuan, an increase of 2.95% year-on-year [21] - Baihua Pharmaceutical's net profit attributable to shareholders increased by 12.45% year-on-year to 25.48 million yuan [21] - Baihua Pharmaceutical's basic earnings per share were 0.0663 yuan [21] Group 14 - Stanley's revenue for the first half of 2025 was 6.391 billion yuan, an increase of 12.66% year-on-year [22][23] - Stanley's net profit attributable to shareholders increased by 18.9% year-on-year to 607 million yuan [22][23] - Stanley plans to distribute a cash dividend of 0.45 yuan per 10 shares [22] Group 15 - Duoli Technology's revenue for the first half of 2025 reached 1.734 billion yuan, an increase of 13.15% year-on-year [24] - Duoli Technology's net profit attributable to shareholders decreased by 28.13% year-on-year to 157 million yuan [24] - Duoli Technology's basic earnings per share were 0.51 yuan [24] Group 16 - Datang Telecom reported a net loss of 81.17 million yuan for the first half of 2025 [25][26] - Datang Telecom's revenue for the first half of 2025 was 275 million yuan, a decrease of 3.32% year-on-year [25][26] - Datang Telecom's basic earnings per share were a loss of 0.0623 yuan [25] Group 17 - Niuwei Co.'s revenue for the first half of 2025 reached 3.404 billion yuan, an increase of 19.96% year-on-year [27][28] - Niuwei Co.'s net profit attributable to shareholders increased by 30.44% year-on-year to 637 million yuan [27][28] - Niuwei Co. plans to distribute a cash dividend of 5.8 yuan per 10 shares [27] Group 18 - ST Zhiyun reported a net loss of 106 million yuan for the first half of 2025 [29][30] - ST Zhiyun's revenue for the first half of 2025 was 89.13 million yuan, a decrease of 63.59% year-on-year [29][30] - ST Zhiyun's basic earnings per share were a loss of 0.37 yuan [29] Group 19 - Huace Testing's revenue for the first half of 2025 reached 2.96 billion yuan, an increase of 6.05% year-on-year [31] - Huace Testing's net profit attributable to shareholders increased by 7.03% year-on-year to 467 million yuan [31] - Huace Testing plans to distribute a cash dividend of 0.5 yuan per 10 shares [31] Group 20 - Taixiang's revenue for the first half of 2025 was 219 million yuan, an increase of 6.57% year-on-year [32] - Taixiang's net profit attributable to shareholders increased by 16.12% year-on-year to 25.30 million yuan [32] - Taixiang's basic earnings per share were 0.2533 yuan [32] Group 21 - Huayi Technology applied for a credit line of up to 165 million yuan from HSBC [33][34] - Huayi Technology will use real estate as collateral for the credit line [33][34] Group 22 - Hengong Precision plans to use up to 70 million yuan of idle raised funds for cash management [35][36] - Hengong Precision will invest in high-security, high-liquidity products with a term not exceeding 12 months [35][36] Group 23 - Tianhe's financial assistance to its associate company has not been repaid [37] - Tianhe provided 243,200 yuan in financial assistance to its associate company [37] Group 24 - Spring and Autumn Electronics' revenue for the first half of 2025 reached 1.926 billion yuan, an increase of 2.62% year-on-year [38] - Spring and Autumn Electronics' net profit attributable to shareholders increased by 248.44% year-on-year to 93.31 million yuan [38] - Spring and Autumn Electronics' basic earnings per share were 0.21 yuan [38] Group 25 - Kingsoft Office's revenue for the first half of 2025 was 2.657 billion yuan, an increase of 10.12% year-on-year [39][40] - Kingsoft Office's net profit attributable to shareholders increased by 3.57% year-on-year to 747 million yuan [39][40] Group 26 - Yanjinpuzi's revenue for the first half of 2025 reached 2.941 billion yuan, an increase of 19.58% year-on-year [41] - Yanjinpuzi's net profit attributable to shareholders increased by 16.70% year-on-year to 373 million yuan [41] Group 27 - Muyuan's revenue for the first half of 2025 was 76.463 billion yuan, an increase of 34.46% year-on-year [43][44] - Muyuan's net profit attributable to shareholders increased by 1169.77% year-on-year to 10.53 billion yuan [43][44] - Muyuan plans to distribute a cash dividend of 9.32 yuan per 10 shares [43][44] Group 28 - Tianwei Food is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [45][46] Group 29 - Alloy Investment's shareholder plans to reduce their stake by no more than 3% [47] - Alloy Investment's shareholder plans to sell up to 11.5531 million shares [47] Group 30 - Rongzhi Rixin's controlling shareholder plans to reduce their stake by no more than 3% [48] - Rongzhi Rixin's controlling shareholder plans to sell up to 1.2318 million shares [48] Group 31 - Yijiahe's shareholders plan to reduce their stake by no more than 2% [49] - Yijiahe's shareholders plan to sell up to 409.72 million shares [49] Group 32 - Dongfeng Group adjusted the upper limit of its share repurchase price to 6.28 yuan per share [50] Group 33 - Jingu's revenue for the first half of 2025 reached 2.123 billion yuan, an increase of 10.04% year-on-year [51] - Jingu's net profit attributable to shareholders increased by 45.36% year-on-year to 30.27 million yuan [51] Group 34 - Yibai Pharmaceutical reported a net loss of 19.9 million yuan for the first half of 2025 [52] - Yibai Pharmaceutical's revenue for the first half of 2025 was 999 million yuan, a decrease of 14.99% year-on-year [52] Group 35 - Yonghui Supermarket reported a net loss of 241 million yuan for the first half of 2025 [53] - Yonghui Supermarket's revenue for the first half of 2025 was 29.948 billion yuan, a decrease of 20.73% year-on-year [53] Group 36 - Suotong Development's net profit increased by 1568.52% year-on-year to 523 million yuan [54] - Suotong Development's revenue for the first half of 2025 was 8.306 billion yuan, an increase of 28.28% year-on-year [54]

Core Viewpoint - Guizhou Yibai Pharmaceutical Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, indicating challenges in the pharmaceutical industry amid economic adjustments and increased competition [1][15][14]. Company Overview - Guizhou Yibai Pharmaceutical is a comprehensive pharmaceutical enterprise focusing on the entire industry chain from traditional Chinese medicine cultivation to production and sales, including chemical drugs, traditional Chinese medicine, and biological drugs [3][6]. - The company operates in various therapeutic areas, including oncology, cardiovascular, gynecology, pediatrics, orthopedics, and respiratory diseases, with a product portfolio of 152 varieties [15][16]. Financial Performance - The company reported operating revenue of approximately 993.12 million yuan, a decrease of 14.99% compared to the same period last year [2][15]. - The total profit for the period was a loss of approximately 23.85 million yuan, with a net profit attributable to shareholders of approximately -19.90 million yuan [2][15]. - The net cash flow from operating activities was approximately 170.55 million yuan, down 16.02% from the previous year [2]. Business Segments - The pharmaceutical industrial segment generated approximately 778.46 million yuan in revenue, down 15.83%, while the medical services segment generated approximately 203.81 million yuan, down 11.69% [15][16]. - The medical services segment includes the operation and management of hospitals and specialized cancer treatment centers, with a focus on providing high-quality medical services [16]. Industry Context - The pharmaceutical industry in China is experiencing a period of adjustment due to economic transformation, with overall revenue and profit declines reported across the sector [11][14]. - The industry is driven by factors such as an aging population, increasing healthcare demands, and government policies aimed at reforming the healthcare system [8][12]. - The market is expected to continue growing, supported by policy initiatives and technological advancements, despite challenges such as rising medical costs and pressure on insurance funds [9][10][12]. Strategic Initiatives - The company is committed to innovation and enhancing its core business capabilities, focusing on research and development, production technology, and sales management [6][14]. - Efforts are being made to integrate AI technology into operations to improve efficiency and decision-making processes [19][20]. - The company aims to expand its product line and market presence through strategic partnerships and collaborations in research and development [17][18].

贵州益佰制药股份有限公司2025 年半年度报告摘要 公司代码：600594 公司简称：益佰制药 贵州益佰制药股份有限公司 贵州益佰制药股份有限公司2025 年半年度报告摘要 第一节 重要提示 展规划，投资者应当到 http://www.sse.com.cn 网站仔细阅读半年度报告全文。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 贵州益佰制药股份有限公司2025 年半年度报告摘要 第二节 公司基本情况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前 股票简称 A股 上海证券交易所 益佰制药 600594 无 联系人和联系方式 董事会秘书 证券事务代表 姓名 蒋先洪 周光欣 电话 0851-84705177 0851-84705177 办公地址 贵州省贵阳市云岩区白云大道220-1号 贵州省贵阳市云岩区白云大道 220-1号 电子信箱 600594@gz100.cn 600594@gz100.cn 单位：元 币种：人民币 本报告期末比上年 本报告期末 上年度末 度末增减(%) 总资产 4,052,321,538.48 4,099,701,241.48 -1 ...

证券代码：600594 证券简称：益佰制药 公告编号:2025-022 贵州益佰制药股份有限公司 第八届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 次会议通知于 2025 年 8 月 8 日以电子邮件等方式送达全体董事、监事及高管， 会议增加临时议案《关于受让控股子公司少数股权的议案》的通知于 2025 年 8 月 19 日以电子邮件等方式送达全体董事、监事及高管，全体董事一致同意增加 临时议案《关于受让控股子公司少数股权的议案》，并同意本次增加临时议案通 知的发出豁免时限的要求，本次会议召集人董事长窦啟玲女士在会议上对此作 出了说明。本次会议于 2025 年 8 月 19 日在公司行政楼会议室以现场加通讯会 议方式召开。 玲女士召集和主持。 本议案在提交公司董事会审议前已经公司第八届董事会审计委员会 2025 年第四次会议审议通过。 详情请参见公司于 2025 年 8 月 21 日披露在《中国证券报》 《证券时报》 《上 二、董事会会议审议情况 本次会议以记名投票表决方 ...

证券代码：600594 证券简称：益佰制药 公告编号：2025-023 贵州益佰制药股份有限公司 第八届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 会议通知于 2025 年 8 月 8 日以电子邮件等方式送达全体监事，会议增加临时议 案《关于受让控股子公司少数股权的议案》的通知于 2025 年 8 月 19 日以电子 邮件等方式送达全体监事，全体监事一致同意增加临时议案《关于受让控股子 公司少数股权的议案》，并同意本次增加临时议案通知的发出豁免时限的要求， 本次会议召集人监事会主席姜韬先生在会议上作出了说明。本次会议于 2025 年 姜韬先生召集和主持。 二、监事会会议审议情况 本次会议以记名投票表决方式审议通过了如下议案： 度报告全文及其摘要》； 详情请参见公司于 2025 年 8 月 21 日披露在《中国证券报》《证券时报》 《上海证券报》《证券日报》和上海证券交易所网站（http://www.sse.com.cn） 上的《贵州益佰制药股份有限公司 2025 年半年度报 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ?股东大会召开日期：2025年9月5日 证券代码：600594 证券简称：益佰制药 公告编号：2025-026 贵州益佰制药股份有限公司 关于召开2025年第一次临时股东大会的通知 ?本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 一、召开会议的基本情况 （一）股东大会类型和届次 （二）股东大会召集人：董事会 （三）投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 （四）现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 5 日 10 点 00 分 召开地点：贵州益佰制药股份有限公司行政楼会议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 5 日 至2025 年 9 月 5 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11 ...